Back to Search
QUYNH-THU LE, M.D.
M.D.
Radiation Oncology Physician
NPI: 1316002116IndividualAccepts Medicare
Specialties, Licenses & Credentials
Radiation Oncology PhysicianPrimary
Radiology — Radiation Oncology
Code: 2085R0001X
G079675(CA)
CMS Specialties
PrimaryRADIATION ONCOLOGY
Education
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO SCHOOL OF MEDICINE
Class of 1993
Research & Publications (20)
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03.
PMID 19667273·J Clin Oncol·2009
4-observational
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
PMID 19364954·J Clin Oncol·2009
3-trial
Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
PMID 19028346·Semin Radiat Oncol·2009
6-review
In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma.
PMID 18258377·Int J Radiat Oncol Biol Phys·2008
8-other
Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.
PMID 17848296·Int J Radiat Oncol Biol Phys·2007
8-other
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
PMID 17707270·Int J Radiat Oncol Biol Phys·2007
8-other
Nasopharyngeal and oropharyngeal carcinomas: target delineation, therapy delivery and stereotactic boost procedures with intensity-modulated/ image-guided radiation therapy.
PMID 17641511·Front Radiat Ther Oncol·2007
6-review
Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.
PMID 17409963·J Thorac Oncol·2006
3-trial
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
PMID 16533775·Clin Cancer Res·2006
4-observational
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
PMID 16532436·Cancer·2006
3-trial
Galectin-1: a link between tumor hypoxia and tumor immune privilege.
PMID 16219933·J Clin Oncol·2005
7-preclinical
A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma.
PMID 16115906·Clin Cancer Res·2005
4-observational
Nonsurgical therapy for stages I and II non-small cell lung cancer.
PMID 15833405·Hematol Oncol Clin North Am·2005
6-review
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
PMID 15328179·Clin Cancer Res·2004
3-trial
Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer.
PMID 14555497·Clin Cancer Res·2003
6-review
Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma.
PMID 12829140·Int J Radiat Oncol Biol Phys·2003
3-trial
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
PMID 12738312·Int J Radiat Oncol Biol Phys·2003
3-trial
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
PMID 12538452·Clin Cancer Res·2003
8-other
Primary radiotherapy for localized orbital MALT lymphoma.
PMID 11849787·Int J Radiat Oncol Biol Phys·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 PASTEUR DR
STANFORD, CA 94305 - Phone
- (650) 723-4000
Quick Facts
- NPI
- 1316002116
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile